

Philip Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2079319/publications.pdf>

Version: 2024-02-01

18
papers

309
citations

1163117

8
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

397
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. Medical Journal of Australia, 2022, 216, 43-52.	1.7	8
2	Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. New England Journal of Medicine, 2022, 386, 1421-1431.	27.0	52
3	A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Blood Advances, 2022, 6, 3494-3506.	5.2	17
4	Skimming information from traumatized tissue. Journal of Thrombosis and Haemostasis, 2022, 20, 1306-1308.	3.8	1
5	R2 and R2* MRI assessment of liver iron content in an undifferentiated diagnostic population with hyperferritinaemia, and impact on clinical decision making. European Journal of Radiology, 2021, 135, 109473.	2.6	10
6	COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Internal Medicine Journal, 2021, 51, 763-768.	0.8	12
7	The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters. Journal of Thrombosis and Haemostasis, 2021, 19, 2094-2095.	3.8	4
8	Australian and New Zealand approach to diagnosis and management of vaccine-induced immune thrombosis and thrombocytopenia. Medical Journal of Australia, 2021, 215, 245.	1.7	29
9	Alemtuzumab induced red cell aplasia and other immune cytopenias – not so ‘pure’. Immunotherapy, 2021, , .	2.0	2
10	Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia. Blood, 2021, 138, 14-14.	1.4	5
11	Altitude exposure as a training & iron overload management strategy post leukemia. Journal of Science and Medicine in Sport, 2020, 23, 75-81.	1.3	2
12	Lifting the fog over ITP. Platelets, 2020, 31, 283-284.	2.3	0
13	Novel scientific approaches and future research directions in understanding ITP. Platelets, 2020, 31, 315-321.	2.3	13
14	The molecular basis of immune-based platelet disorders. Clinical Science, 2020, 134, 2807-2822.	4.3	1
15	Polycythaemia Secondary to Hormone Replacement Therapy with Tibolone. Case Reports in Hematology, 2017, 2017, 1-2.	0.4	0
16	Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. Haematologica, 2015, 100, 623-632.	3.5	84
17	A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood, 2015, 126, 500-503.	1.4	60
18	Presentation and outcome of idiopathic thrombocytopenic purpura in a single Australian centre. Internal Medicine Journal, 2012, 42, 841-845.	0.8	9